PDF herunterladen
Aktuelle Rheumatologie 2016; 41(02): 152-156
DOI: 10.1055/s-0041-109888
Übersichtsarbeit
© Georg Thieme Verlag KG Stuttgart · New York

Hämatopoetische Stammzelltransplantation bei Autoimmunerkrankungen – Wo stehen wir aktuell?

Haematopoietic Stem Cell Transplantation in Autoimmune Diseases – Where are We Today?
J. C. Henes
1   Centre for Interdisciplinary Clinical Immunology, Rheumatology and Auto-inflammatory Diseases and Internal Medicine II, University Hospital Tuebingen, Tuebingen
,
S. Wirths
2   Internal Medicine II (Oncology, Hematology, Rheumatology, Immunology, Pulmonology), University Hospital Tuebingen, Tuebingen
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
18. Dezember 2015 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Zusammenfassung

Die autologe Stammzelltransplantation (aSCT) ermöglicht bei vielen, unterschiedlichen Autoimmunerkrankungen das Erreichen einer langfristigen Verbesserung oder gar Remission. Allerdings ist die Therapie mit einem therapieassoziierten Risiko verbunden. Die therapieassoziierte Mortalität (TRM) hängt maßgeblich von der Grunderkrankung, der damit verbunden Organbeteiligung, aber auch von der Erfahrung der transplantierenden Zentren ab. Über die Jahre hat sich die aSCT als Therapieoption vor allem bei den schweren, therapierefraktären Patienten und bei Krankheitsbildern ohne neue Therapiemöglichkeiten etabliert. Dies führt häufig dazu, dass Patienten diese Therapie erst (zu) spät angeboten wird. Je nach Krankheitsbild – besonders ausgeprägt bei der Systemischen Sklerose – bestehen zu diesem Zeitpunkt bereits schwere Organschädigungen, welche wiederum die TRM dtl. erhöhen. Für die Zukunft sollten daher bessere Prognosefaktoren definiert, sowie weniger toxischer Therapieregime etabliert werden.

Abstract

Autologous stem cell transplantation (aSCT) leads to long-term improvement or even remission in various autoimmune diseases. However, this treatment is associated with a risk. Treatment-related mortality (TRM) mainly depends on the underlying disease and the associated organ involvement, but also on the level of experience that transplantation centres have with aSCT. Over the years, aSCT has become an established treatment option, especially for patients with a severe treatment-refractory disease and in diseases for which there are no new treatment options. This often leads to the fact that patients are offered this treatment with delay or even too late. In some diseases, especially systemic sclerosis, severe organ damage is already present at that point in time, which, in turn, leads to a significant increase in TRM. Therefore, new and reliable prognostic factors should be defined and less toxic treatment regimes established for the future.

Schlüsselworte:

Hämatopoietische Stammzelltransplantation - Autoimmunerkrankung - Systemische Sklerose - Multiple Sklerose - chron. entzündliche Darmerkrankungen

Key words

hematopoietic stem cell transplantation - autoimmune disease - systemic sclerosis - multiple sclerosis - inflammatory bowel disease
 

  • Literatur

  • 1 Tamm M, Gratwohl A, Tichelli A et al. Autologous haemopoietic stem cell transplantation in a patient with severe pulmonary hypertension complicating connective tissue disease. Ann Rheum Dis 1996; 55: 779-780
    CrossrefPubMedGoogle Scholar
  • 2 Gratwohl A, Passweg J, Bocelli-Tyndall C et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases. Bone Marrow Transpl 2005; 35: 869-879
    CrossrefPubMedGoogle Scholar
  • 3 Farge D, Labopin M, Tyndall A et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years’ experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases. Haematologica 2010; 95: 284-292
    CrossrefPubMedGoogle Scholar
  • 4 Binks M, Passweg JR, Furst D et al. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease. Ann Rheum Dis 2001; 60: 577-584
    CrossrefPubMedGoogle Scholar
  • 5 Farge D, Marolleau JP, Zohar S et al. Autologous bone marrow transplantation in the treatment of refractory sys- temic sclerosis: early results from a French multicentre phase I-II study. Br J Haematol 2002; 119: 726-739
    CrossrefPubMedGoogle Scholar
  • 6 Henes JC, Schmalzing M, Vogel W et al. Optimization of autologous stem cell transplantation for systemic sclerosis – a single-center longterm experience in 26 patients with severe organ manifestations. J Rheumatol 2012; 39: 269-275
    CrossrefPubMedGoogle Scholar
  • 7 Burt RK, Shah SJ, Dill K et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet 2011; 378: 498-506
    CrossrefPubMedGoogle Scholar
  • 8 van Laar JM, Farge D, Sont JK et al. Autologous hematopoietic stem cell transplantation versus intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 2014; 311: 2490-2498
    CrossrefPubMedGoogle Scholar
  • 9 Henes JC, Koetter I, Horger M et al. Autologous stem cell transplantation with thiotepa-based conditioning in patients with systemic sclerosis and cardiac manifestations. Rheumatology 2014; 53: 919-922
    CrossrefPubMedGoogle Scholar
  • 10 Saccardi R, Tyndall A, Coghlan G et al. Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis. Bone Marrow Transpl 2004; 34: 877-881
    CrossrefPubMedGoogle Scholar
  • 11 Burt RK, Oliveira MC, Shah SJ et al. Cardiac involvement and treatment-related mortality after non-myeloablative haemopoietic stem-cell transplantation with unselected autologous peripheral blood for patients with systemic sclerosis: a retrospective analysis. Lancet 2013; 381: 1116-1124
    CrossrefPubMedGoogle Scholar
  • 12 Nash RA, McSweeney PA, Crofford LJ et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: Long-term follow-up of the US multicenter pilot study. Blood 2007; 110: 1388-1396
    CrossrefPubMedGoogle Scholar
  • 13 Craciunescu OI, Steffey BA, Kelsey CR et al. Renal shielding and dosimetry for patients with severe systemic sclerosis receiving immunoablation with total body irradiation in the scleroderma: cyclophosphamide or transplantation trial. Int J Radiat Oncol Biol Phys 2011; 15: 1248-1255
    PubMedGoogle Scholar
  • 14 Fassas A, Anagnostopoulos A, Kazis A et al. Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study. Bone Marrow Transplant 1997; 20: 631-638
    CrossrefPubMedGoogle Scholar
  • 15 Nash RA, Bowen JD, McSweeney PA et al. High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood 2003; 102: 2364-2372
    CrossrefPubMedGoogle Scholar
  • 16 Kozák T, Havrdová E, Pit’ha J et al. High-dose immunosuppressive therapy with PBPC support in the treatment of poor risk multiple sclerosis. Bone Marrow Transplant 2000; 25: 525-531
    CrossrefPubMedGoogle Scholar
  • 17 Su L, Xu J, Ji BX et al. Autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Int J Hematol 2006; 84: 276-281
    CrossrefPubMedGoogle Scholar
  • 18 Burt RK, Loh Y, Cohen B et al. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. Lancet Neurol 2009; 8: 244-253
    CrossrefPubMedGoogle Scholar
  • 19 Shevchenko JL, Kuznetsov AN, Ionova TI et al. Autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis. Exp Hematol 2012; 40: 892-898
    CrossrefPubMedGoogle Scholar
  • 20 Saccardi R, Mancardi GL, Solari A et al. Autologous HSCT for severe progressive multiple sclerosis in a multi-center trial: impact on disease activity and quality of life. Blood 2005; 105: 2601-2607
    CrossrefPubMedGoogle Scholar
  • 21 Mancardi GL, Sormani MP, Gualandi F et al. Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial. Neurology 2015; 10: 981-988
    PubMedGoogle Scholar
  • 22 Drakos PE, Nagler A, Or R. Case of Crohn’s disease in bone marrow transplantation. Am J Hematol 1993; 43: 157-158
    CrossrefPubMedGoogle Scholar
  • 23 Lopez-Cubero SO, Sullivan KM, McDonald GB. Course of Crohn’s disease after allogeneic marrow transplantation. Gastroenterology 1998; 114: 433-440
    CrossrefPubMedGoogle Scholar
  • 24 Ditschkowski M, Einsele H, Schwerdtfeger R et al. Improvement of inflammatory bowel disease after allogeneic stem-cell transplantation. Transplantation 2003; 75: 1745-1747
    CrossrefPubMedGoogle Scholar
  • 25 Kashyap A, Forman SJ. Autologous bone marrow transplantation for non-Hodgkin’s lymphoma resulting in long-term remission of coincidental Crohn’s disease. Br J Haematol 1998; 103: 651-652
    CrossrefPubMedGoogle Scholar
  • 26 Burt RK, Traynor A, Oyama Y et al. High-dose immune suppression and autologous hematopoietic stem cell transplantation in refractory Crohn disease. Blood 2003; 101: 2064-2066
    CrossrefPubMedGoogle Scholar
  • 27 Craig RM, Traynor A, Oyama Y et al. Hematopoietic stem cell transplantation for severe Crohn’s disease. Bone Marrow Transplant 2003; 32 (Suppl. 01) S57-S59
    CrossrefPubMedGoogle Scholar
  • 28 Oyama Y, Craig RM, Traynor AE et al. Autologous hematopoietic stem cell transplantation in patients with refractory Crohn’s disease. Gastroenterology 2005; 128: 552-563
    CrossrefPubMedGoogle Scholar
  • 29 Burt RK, Craig RM, Milanetti F et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in patients with severe anti-TNF refractory Crohn disease: long-term follow-up. Blood 2010; 116: 6123-6132
    CrossrefPubMedGoogle Scholar
  • 30 Hasselblatt P, Drognitz K, Potthoff K et al. Remission of refractory Crohn’s disease by high-dose cyclophosphamide and autologous peripheral blood stemcell transplantation. Aliment Pharmacol Ther 2012; 36: 725-735
    CrossrefPubMedGoogle Scholar
  • 31 Burt RK, Traynor A, Statkute L et al. Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus. JAMA 2006; 295: 527-535
    CrossrefPubMedGoogle Scholar
  • 32 Alchi B, Jayne D, Labopin M et al. Autologous haematopoietic stem cell transplantation for systemic lupus erythematosus: data from the European Group for Blood and Marrow Transplantation registry. Lupus 2013; 22: 245-253
    CrossrefPubMedGoogle Scholar
  • 33 Alexander T, Thiel A, Rosen O et al. Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system. Blood 2009; 113: 214-223
    CrossrefPubMedGoogle Scholar
  • 34 Burt R, Testor A, Craig R et al. Hematopoietic stem cell transplantation for autoimmune diseases: what have we learned?. Journal of Autoimmunity 2008; 30: 116-120
    CrossrefPubMedGoogle Scholar
  • 35 Bingham SJ, Snowden J, McGonagle D et al. Autologous stem cell transplantation for rheumatoid arthritis–interim report of 6 patients. The Journal of Rheumatology 2001; 64: 21-24
    PubMedGoogle Scholar
  • 36 Teng YK, Verburg RJ, Sont JK et al. Long-term follow-up of health status in patients with severe rheumatoid arthritis after high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation. Arthritis and Rheumatism 2005; 52: 2272-2276
    CrossrefPubMedGoogle Scholar
  • 37 Verburg RJ, Sont JK, van Laar JM. Reduction of joint damage in severe rheumatoid arthritis by high-dose chemotherapy and autologous stem cell transplantation Arthritis and Rheumatism 2005; 52: 421-424
    PubMed
  • 38 Snowden J, Passweg J, Moore J et al. Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: a report from the EBMT and ABMTR. Journal of Rheumatology 2004; 31: 482-488
    PubMedGoogle Scholar
  • 39 Brinkman DM, de Kleer IM, ten Cate R et al. Autologous stem cell transplantation in children with severe progressive systemic or polyarticular juvenile idiopathic arthritis: long-term follow-up of a prospective clinical trial. Arthritis and Rheumatism 2007; 56: 2410-2421
    CrossrefPubMedGoogle Scholar
  • 40 Abinun M, Flood TJ, Cant AJ et al. Autologous T cell depleted haematopoietic stem cell transplantation in children with severe juvenile idiopathic arthritis in the UK (2000–2007). Molecular Immunology 2009; 47: 46-51
    CrossrefPubMedGoogle Scholar